Physician's Weekly has published a new review rounding up the evidence on complementary treatment strategies for psoriasis — a condition that, for most patients, is managed with topical steroids, phototherapy and biologics measured against hard endpoints like PASI 75 and PASI 90.

The review lands in a field where patient behavior is already far ahead of the data. Dermatology clinics routinely see psoriasis patients using fish oil, turmeric, acupuncture, dietary changes or stress-reduction techniques alongside — or occasionally instead of — their prescribed regimens. The Physician's Weekly piece attempts to sort which of those add-on strategies carry evidence and which rest on tradition or marketing.

Why complementary approaches matter in psoriasis

Psoriasis is a chronic immune-mediated disease, and even the best modern therapies rarely clear every patient completely. That gap — between what biologics deliver and what patients want — is where complementary strategies live.

The practical framing matters here. Complementary means alongside standard treatment. Alternative means instead of it. The evidence base for the first category is growing; for the second, dermatologists have long warned that abandoning proven therapy for unproven remedies risks flares, joint damage and, in erythrodermic cases, serious outcomes.

What does this change for practicing dermatologists?

For clinicians, the value of a review like this is triage. Patients will ask about supplements, diets and mind-body practices whether or not their physician raises the topic first. A clinician who knows which strategies have supporting data can guide that conversation rather than watch it happen without supervision.

The review's broader signal is that complementary strategies belong in the conversation as adjuncts, not replacements. Any add-on should be weighed against three questions:

• Does it interact with the patient's psoriasis medication?
• Does the evidence support benefit, or merely tolerate the practice as harmless?
• Does the cost and effort displace something that works better?

The evidence-class caveat

Complementary-medicine research in dermatology carries a structural problem: many studies are small, short, and unblinded, which makes them vulnerable to placebo effects that are notoriously strong in visible, stress-reactive diseases like psoriasis. Reviews such as this one earn their keep precisely by grading that evidence rather than aggregating headlines.

That grading function is the real news value of the piece. Physicians reading it get a consolidated view of what complementary interventions have been tested in psoriasis populations, at what rigor, and with what outcomes — information that is otherwise scattered across journals patients never see.

The patient-access angle

There's also an equity dimension. Complementary strategies — diet modification, exercise, stress management — are often cheaper than copays for specialty drugs, which is one reason uptake is high among patients who struggle with access or cost barriers. If any of these approaches carry even modest evidence, that matters disproportionately for the patients a dermatology practice sees least often.

What does this change tomorrow morning in clinic? Probably a better-informed answer when the fish-oil question comes up — and it always comes up.

Physician's Weekly's review signals a maturing conversation: complementary strategies in psoriasis are moving from the fringe into evidence-graded medicine, and expect follow-up trial data to sharpen those grades in the next few years.